Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd., a global ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Previously, SMM made the following reminder about the discontinuation of high-grade NPI price updates by region: SMM Announcement: The Publication of High-Grade NPI Prices by Region Will Soon Be ...

Lead Prices Reverse and Pull Back, Spot Market Transactions Show Significant Divergence】 SMM March 28: In the Shanghai market, Chihong lead was quoted at 17,425-17,475 yuan/mt, with a premium of 0-50 ...

As the clock ticks down to the highly anticipated showdown between the China national football team and Australia, excitement is palpable among fans. This eighth round of the 2026 FIFA World Cup Asia ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...